Oscar Health (OSCR) vs Veracyte (VCYT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Oscar Health (OSCR) has outperformed Veracyte (VCYT) over the past year, gaining 51.8% versus a gain of 24.2%. Over five years, OSCR leads with a +108.8% price change compared with -3.5% for VCYT. Oscar Health is the larger company by market cap ($10.30 billion vs $3.64 billion), about 2.8 times the size.
On valuation, Oscar Health trades at a lower forward P/E (15.4x vs 23.2x for Veracyte). Veracyte converts more of its revenue into profit, with a net margin of 12.8% versus -3.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OSCR | VCYT |
|---|---|---|
| Share price | $33.37 | $45.23 |
| Market cap | $10.30B | $3.64B |
| 1-day change | +0.82% | +3.74% |
| YTD return | +130.34% | +3.56% |
| 1-year return | +51.83% | +24.22% |
| 5-year return | +108.83% | -3.45% |
| P/E ratio (TTM) | 25.87 | 32.31 |
| Forward P/E | 15.41 | 23.25 |
| EPS (TTM) | $1.29 | $1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $11.70B | $517.14M |
| Revenue growth (YoY) | +27.50% | +16.01% |
| Net income (latest FY) | $-443.15M | $66.35M |
| Gross margin | — | 70.10% |
| Operating margin | -3.39% | 11.17% |
| Net margin | -3.79% | 12.83% |
| 52-week high | $34.48 | $60.91 |
| 52-week low | $10.69 | $29.46 |
| Distance from 52-week high | -3.22% | -25.74% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +6.08% | +29.16% |
| Average volume | 5.20M | 1.36M |
| Shares outstanding | 273.47M | 80.39M |
| Employees | 2,305 | 755 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Oscar Health is about 2.8 times larger than Veracyte by market value ($10.30B vs $3.64B).
- OSCR has outperformed VCYT by 27.6 percentage points over the past year.
- Veracyte is more profitable, keeping 12.8 cents of every revenue dollar as net income versus -3.8 cents for Oscar Health.
- Oscar Health grew revenue faster in its latest fiscal year (+27.50% vs +16.01%).
About Oscar Health
OSCR stock →Oscar Health, Inc. operates as a healthcare technology company in the United States.
Health Care · Medical Specialities · 2,305 employees
About Veracyte
VCYT stock →Veracyte, Inc. operates as a diagnostics company in the United States and internationally.
Health Care · Medical Specialities · 755 employees
OSCR vs VCYT FAQ
Which is bigger, Oscar Health or Veracyte?
Oscar Health (OSCR) is larger, with a market capitalization of $10.30B compared with $3.64B for Veracyte (VCYT).
Which stock has performed better over the past year, OSCR or VCYT?
OSCR returned +51.83% over the past 12 months, compared with +24.22% for VCYT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, OSCR or VCYT?
OSCR has the lower trailing P/E at 25.9, versus 32.3 for VCYT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Oscar Health and Veracyte in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.